You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
欧康维视(01477.HK)候选药物获批第二项III期临床试验
阿思达克 03-04 04:36
欧康维视生物-B(01477.HK)公布,主要候选药物之一OT-301(NCX 470)近期获中国国家药品监督管理局药品审评中心批准於中国启动其第二项III期临床试验。

NCX 470由Nicox与公司共同开发,是同类首创的一氧化氮(NO)供体型贝美前列素类似物,用於降低开角型青光眼及高眼压症患者的眼内压。

2018年12月,集团获Nicox独家许可,在大中华地区开发、制造、委托制造、进口、出口及销售OT-301(NCX 470),并於去年3月将独家权利扩大至韩国及东南亚12个国家。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account